Our journey in precision oncology

Key milestones in CHOSA’s journey to improve platinum chemotherapy through biologically informed patient selection.

2025
  • New clinical data supporting the predictive value of Platin-DRP® (ETOP/EORTC collaboration)
  • Validation of Platin-DRP® across additional diagnostic platforms (NanoString)
  • International patent application filed for biomarker-guided platinum combination therapies
  • Expanded engagement with the global oncology community (ASCO, ESMO)
  • International recognition through the Jiangning Global Entrepreneurship Competition
2024
  • Continued scientific dissemination of Platin-DRP® clinical data
  • Expanded engagement with the global oncology research community
  • Ongoing development of biomarker-guided platinum treatment strategies
  • Strengthened CHOSA’s position within precision oncology
2023
  • Prospective clinical study results for Platin-DRP® presented (ASCO)
  • Demonstrated predictive value of Platin-DRP® in metastatic breast cancer
  • Strengthened the scientific foundation for biomarker-guided platinum therapy
  • Established presence within leading life science clusters in BioInnovation Institute (Copenhagen, Denmark) and Medicon Village (Lund, Sweden)
2022
  • CHOSA Oncology was founded by experienced oncology clinicians and biotech leaders
  • Merger with RhoVac AB, expanding development capabilities and global reach
  • Advanced development of LiPlaCis® and strengthened the scientific foundation for DRP-based platinum treatment guidance

Learn more about CHOSA

Our Purpose
CHOSA Team